The Impact of Combined Oral Sildenafil and Inhaled Nitric Oxide for Treating Persistent Pulmonary Hypertension of the Newborn: A Single Center Experience

Objective: We aimed to compare the effect of the combined therapy, sildenafil and inhaled nitric oxide with inhaled nitric oxide monotherapy for the treatment of Pulmonary Hypertension of the Newborn. Study Design: Newborn infants (gestational age greater than 34 weeks) who were diagnosed with pulmo...

Full description

Saved in:
Bibliographic Details
Main Authors: Hayriye Gozde Kanmaz (Author), Mehmet Büyüktiryaki (Author), Şerife Suna Oğuz (Author), Evrim Dizdar Alyamac (Author), Fatma Nur Sarı (Author), Fuat Emre Canpolat (Author), Nurdan Uras (Author)
Format: Book
Published: Medical Network, 2017-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_9499f1672a834f79a49eeef3df9669a2
042 |a dc 
100 1 0 |a Hayriye Gozde Kanmaz  |e author 
700 1 0 |a Mehmet Büyüktiryaki  |e author 
700 1 0 |a Şerife Suna Oğuz  |e author 
700 1 0 |a Evrim Dizdar Alyamac  |e author 
700 1 0 |a Fatma Nur Sarı  |e author 
700 1 0 |a Fuat Emre Canpolat  |e author 
700 1 0 |a Nurdan Uras  |e author 
245 0 0 |a The Impact of Combined Oral Sildenafil and Inhaled Nitric Oxide for Treating Persistent Pulmonary Hypertension of the Newborn: A Single Center Experience 
260 |b Medical Network,   |c 2017-08-01T00:00:00Z. 
500 |a 1300-4751 
500 |a 10.21613/GORM.2016.656 
520 |a Objective: We aimed to compare the effect of the combined therapy, sildenafil and inhaled nitric oxide with inhaled nitric oxide monotherapy for the treatment of Pulmonary Hypertension of the Newborn. Study Design: Newborn infants (gestational age greater than 34 weeks) who were diagnosed with pulmonary hypertension between December 2008 and 2010 were retrospectively evaluated. Group I (n=14) received monotherapy with inhaled nitric oxide and Group II (n=9) received combined therapy with inhaled nitric oxide and oral sildenafil. Primary outcome was to compare the duration of inhaled nitric oxide therapy between groups. Results: Demographic characteristics were similar between the groups. Combination therapy was associated with early weaning of inhaled nitric oxide (4.8±1.5 vs. 13.5±7.6 hours). The duration of inhaled nitric oxide therapy was slightly shorter in combined therapy group (75[24-125] vs. 109[24-210] hours), however, the difference was insignificant (p=0.2). The incidence of mortality and neonatal outcomes were similar between the groups (p>0.05). Conclusion: Combined therapy did not result in shorter duration of inhaled nitric oxide therapy. Further well designed and larger studies that will elucidate the benefits of combination therapies and optimal therapy whereinhaled nitric oxide is not available are warranted. 
546 |a EN 
690 |a Pulmonary hypertension, Newborn, Sildenafil, İnhaled nitric oxide 
690 |a Gynecology and obstetrics 
690 |a RG1-991 
655 7 |a article  |2 local 
786 0 |n Gynecology Obstetrics & Reproductive Medicine, Vol 23, Iss 2, Pp 100-104 (2017) 
787 0 |n http://gorm.com.tr/index.php/GORM/article/view/656 
787 0 |n https://doaj.org/toc/1300-4751 
856 4 1 |u https://doaj.org/article/9499f1672a834f79a49eeef3df9669a2  |z Connect to this object online.